JP2015536949A - 細菌感染症のための抗生物質を用いる方法および組成物 - Google Patents

細菌感染症のための抗生物質を用いる方法および組成物 Download PDF

Info

Publication number
JP2015536949A
JP2015536949A JP2015540824A JP2015540824A JP2015536949A JP 2015536949 A JP2015536949 A JP 2015536949A JP 2015540824 A JP2015540824 A JP 2015540824A JP 2015540824 A JP2015540824 A JP 2015540824A JP 2015536949 A JP2015536949 A JP 2015536949A
Authority
JP
Japan
Prior art keywords
antibiotic
administered
oxacillin
subject
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536949A5 (https=
Inventor
ロバート エス． ダウム
ロバート エス． ダウム
スーザン ボイル—バブラ
スーザン ボイル―バブラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2015536949A publication Critical patent/JP2015536949A/ja
Publication of JP2015536949A5 publication Critical patent/JP2015536949A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2015540824A 2012-11-01 2013-11-01 細菌感染症のための抗生物質を用いる方法および組成物 Pending JP2015536949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721310P 2012-11-01 2012-11-01
US61/721,310 2012-11-01
PCT/US2013/068085 WO2014071198A1 (en) 2012-11-01 2013-11-01 Antibiotic methods and compositions for bacteria infections

Publications (2)

Publication Number Publication Date
JP2015536949A true JP2015536949A (ja) 2015-12-24
JP2015536949A5 JP2015536949A5 (https=) 2016-12-15

Family

ID=50628103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540824A Pending JP2015536949A (ja) 2012-11-01 2013-11-01 細菌感染症のための抗生物質を用いる方法および組成物

Country Status (4)

Country Link
US (1) US9861619B2 (https=)
EP (1) EP2916653A4 (https=)
JP (1) JP2015536949A (https=)
WO (1) WO2014071198A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516055A (ja) * 2013-03-15 2016-06-02 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 細菌感染症に対する方法及び組成物
CN114794129B (zh) * 2021-06-21 2023-09-26 广西壮族自治区亚热带作物研究所（广西亚热带农产品加工研究所） 一种防治澳洲坚果炭疽病的农药组合物
CN113599398B (zh) * 2021-09-14 2024-01-26 中国农业科学院兰州畜牧与兽药研究所 一种治疗犊牦牛肠型大肠杆菌病的药物组合物及制备方法
CN114259485A (zh) * 2021-12-14 2022-04-01 华中科技大学协和深圳医院 苯溴马隆用于抗金黄色葡萄球菌及其生物被膜感染的用途
CN114456189B (zh) * 2022-02-23 2023-03-31 安阳工学院 一种岩白菜素磺酸酯衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272701A (en) * 1962-02-27 1966-09-13 Vineland Lab Inc Free flowing medicated drinking water for poultry and animals
FR2645018A2 (fr) * 1987-06-02 1990-10-05 Boulay Maurice Composition destinee a lutter contre les staphilocoques, les champignons et autres parasites
JP2002538108A (ja) * 1999-03-05 2002-11-12 ニュートリション・トゥエンティワン ブドウ球菌感染症の治療のための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
ITMI20031011A1 (it) * 2003-05-20 2004-11-21 Vanetta S P A Composti biocidi per il trattamento delle acque.
US20070258996A1 (en) * 2005-12-23 2007-11-08 The Sterilex Corporation Antimicrobial compositions
US20100234348A1 (en) 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
US20120064125A1 (en) * 2009-04-17 2012-03-15 Horswill Alexander R Agr-mediated inhibition of methicillin resistant staphylococcus aureus
EP2243482A1 (en) 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
WO2013103780A1 (en) 2012-01-06 2013-07-11 Trustees Of Boston University Compositions and methods to boost endogenous ros production from bacteria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272701A (en) * 1962-02-27 1966-09-13 Vineland Lab Inc Free flowing medicated drinking water for poultry and animals
FR2645018A2 (fr) * 1987-06-02 1990-10-05 Boulay Maurice Composition destinee a lutter contre les staphilocoques, les champignons et autres parasites
JP2002538108A (ja) * 1999-03-05 2002-11-12 ニュートリション・トゥエンティワン ブドウ球菌感染症の治療のための組成物および方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB. AGENTS CHEMOTHERA., 1984, VOL.25, NO.6, PP.687-689, JPN6017026284, ISSN: 0003799716 *
ANTIMICROB. AGENTS CHEMOTHERA., 1994, VOL.38, NO.3, PP.576-579, JPN6017026286, ISSN: 0003799717 *
ANTIMICROB. AGENTS CHEMOTHERA., 1995, VOL.39, NO.6, PP.1324-1328, JPN6017026288, ISSN: 0003799718 *
CHEMOTHERAPY, 1988, VOL.34, NO.2, PP.117-126, JPN6017026283, ISSN: 0003799715 *
J. KOREAN SOC. MICROBIOL., 1995, VOL.30, NO.1, PP.23-36, JPN6017026282, ISSN: 0003799714 *
J. LAB. CLIN. MED., 1960, VOL.56, PP.83-104, JPN6017026291, ISSN: 0003799721 *
JPN. J. ANTIBIOT., VOL.29, NO.5, PP.559-570, JPN6017026290, ISSN: 0003799720 *
感染症雑誌, VOL.73, NO.4, PP.291-297, JPN6017026289, ISSN: 0003799719 *

Also Published As

Publication number Publication date
US9861619B2 (en) 2018-01-09
EP2916653A1 (en) 2015-09-16
WO2014071198A1 (en) 2014-05-08
US20150283120A1 (en) 2015-10-08
EP2916653A4 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
EP3003307B1 (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
TWI690317B (zh) 用於治療抗藥性細菌感染之組合療法
DK2337575T3 (en) A method of treatment with single doses of oritavancin
US20130203726A1 (en) FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
US20170273954A1 (en) Methods and compositions for bacteria infections
US20140128399A1 (en) Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
JP2015536949A (ja) 細菌感染症のための抗生物質を用いる方法および組成物
US20200261440A1 (en) Zinc ionophores and uses thereof
US12016874B2 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
JP4693049B2 (ja) 薬剤耐性黄色ブドウ球菌感染症治療のための医薬組成物
KR101649675B1 (ko) 황색포도상구균에 대한 항균 조성물
US20210332095A1 (en) Infection-induced endothelial amyloid compositions as antimicrobials
US20180021277A1 (en) Anti-virulence compositions and methods
WO2013066469A2 (en) Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics
Boyle-Vavra c12) United States Patent
WO2024128238A1 (ja) 細菌感染症の治療剤
EP3294317B1 (en) Enhanced antibiotic composition
US20180280321A1 (en) Compositions and methods that inhibit quorum sensing
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
HK1223305B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180521